Sugammadex Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0011 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
18/01/2024 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
IAIN/0009/G 
This was an application for a group of variations. 
14/12/2023 
Annex II and 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
PL 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
B.II.e.7.a - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Deletion of a supplier 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.III.2.z - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Other 
variation 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IB/0008 
B.II.b.3.z - Change in the manufacturing process of 
31/08/2023 
n/a 
the finished or intermediate product - Other variation 
N/0007 
Minor change in labelling or package leaflet not 
08/06/2023 
15/09/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0006 
B.II.b.1.a - Replacement or addition of a 
21/04/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0004/G 
This was an application for a group of variations. 
05/04/2023 
n/a 
B.I.a.3.b - Change in batch size (including batch size 
ranges) of AS or intermediate - Downscaling down to 
10-fold 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
Page 3/5 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IB/0005/G 
This was an application for a group of variations. 
15/03/2023 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
IB/0002/G 
This was an application for a group of variations. 
05/10/2022 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.2.a - Change in test procedure for the finished 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Minor changes to an approved test 
procedure 
IAIN/0003 
B.II.b.2.c.1 - Change to importer, batch release 
29/09/2022 
15/09/2023 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0001 
To update sections 4.2, 4.8, 5.1 and 5.2 of the SmPC 
11/05/2022 
02/06/2022 
SmPC, 
To update sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and 
and sections 3 of the PL, in order to change posology 
Labelling and 
sections 3 of the PL, in order to change posology 
recommendations and update safety, efficacy and 
PL 
recommendations and update safety, efficacy and 
pharmacokinetic information in children and 
adolesents (2 - 17 years). Furthermore the MAH has 
taken this oportunity to amend some local 
representatives. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
pharmacokinetic information in children and adolesents (2 - 
17 years). Furthermore the MAH has taken this oportunity 
to amend some local representatives. 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
